Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Breast cancer effect

Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer effects on body composition and lipids. Br J Cancer 2006 95(2) 153-8. [Pg.161]

Mozaffari F et al. NK-cell and T-cell functions in patients with breast cancer effects of surgery and adjuvant chemo- and radiotherapy. Br J Cancer 2007 97 105-111. [Pg.396]

USP (Megace) testolactone USP [968-93 ] C19H24O3 300.40 (61) or endrome-trium breast cancer hyper-calcemia common side effects of steroids fluid retention ... [Pg.443]

In adults, a few areas may require further study. For example, there is a report of soya consumption causing an increased incidence of hyperplastic epithelial cells in the nipple aspirate fluid of pre- and postmenopausal women.This could constitute a risk factor for breast cancer. Also, the use in herbal medicine of particular plants emphasises that these species have the potential to cause physiological changes. Consequently, the increasing public interest in the use of herbal medicines could lead to unintended (adverse) effects, particularly as most... [Pg.129]

Clinical trials showed therapeutic efficacy in a broad spectrum of tumors these include SCLC, testicular tumors, sarcomas, breast cancer, renal cell cancer, pancreatic tumors and lymphomas. Ifosfamide is less myelosuppressive than cyclophosphamide but is more toxic to the bladder. Therefore it is recommended that ifosfamide is coadministered with the thiol compound mesna to avoid hemorrhagic cystitis and to reduce the risk of developing bladder cancer. Other side effects include neurotoxicity and myelosuppression. [Pg.55]

Capecitabine is used for the treatment of colorectal and breast cancers. It is contraindicated in patients with known hypersensitivity to capecitabine or any of its components or to 5-fluorouracil and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. The use of capecitabine is restricted in patients with severe renal impairment. The drag can induce diarrhea, sometimes severe. Other side effects include anemia, hand-foot syndrome, hyperbilirubinemia, nausea, stomatitis, pyrexia, edema, constipation, dyspnea, neutropenia, back pain, and headache. Cardiotoxicity has been observed with capecitabine. A clinically important drag interaction between capecitabine and warfarin has been demonstrated. Care should be exercised when the drag is co-administered with CYP2X9 substrates. [Pg.150]

Glucocorticoids have inhibitory (apoptotic) effects on lymphocyte proliferation and are used to treat leukemias and lymphomas. Estrogens (fosfestrol) are used to block the effect of androgens in prostate cancer. Progestogens (megestrol, medroxyprogesteroneacetate) have been useful for treating endometrial carcinoma, renal tumors, and breast cancer. [Pg.155]

Recombinant humanized monoclonal antibodies have been used recently to target antigens that are preferentially located on cancer cells. Examples include trastuzumab and rituximab which are used to treat HER2 positive breast cancer and B-cell type lymphomas, respectively. Unwanted side effects include anaphylactic reactions. [Pg.156]

Antineoplastic agents that cannot be grouped under subheadings 1-9 include miltefosine which is an alkylphosphocholine that is used to treat skin metastasis of breast cancer, and crispantase which breaks down asparagine to aspartic acid and ammonia. It is active against tumor cells that lack the enzyme asparaginase, such as acute lymphoblastic leukemia cells. Side effects include irritation of the skin in the case of miltefosine and anaphylactic reactions in the case of crispantase. Another recent development is the proteasome inhibitor bortezomib which is used to treat multiple myeloma. [Pg.156]

Anastrazole is a nonsteroidal, type H, aromatase inhibitor that is 200 times more potent than aminoglutethimide. It is eliminated primarily via hqDatic metabolism, has a terminal half life of 50 h with steady state concentrations achieved approximately 10 days with once daily dosing regimens. It is administered orally at a dose of 1 mg/day that achieves near maximal aromatase inhibition and hence estrogen suppression in breast cancer patients. No effect on adrenal steroidogenesis has been observed at up to ten times the daily recommended dose. When used in the metastatic setting, anastrozole has been shown... [Pg.220]

Studies with fenretinide in woman with stage I breast cancer did not show an overall effect of decreasing the risk of contralateral breast cancer. A protective effect could only be observed in premenopausal women, probably due to the modulation of the insulin-like growth factor 1 (IGF-1) by fenretinide in this population. [Pg.1076]

Although the positive effects of ERT have been well established, it has been shown that the cell proliferative actions of estrogen can increase the incidence of breast cancer in some patients. In addition, duration of exposure to physiological levels of unopposed estrogens is an established risk factor for breast, uterine, and ovarian cancer. In an effort to attain pharmaceutical agents that oppose the carcinogenic... [Pg.1113]

STAR trial (Study of tamoxifen and raloxifene), which was completed in 2006, demonstrated additional utility of raloxifene in the prevention and treatment of breast cancer. In fact, the absence of associated uterotrophic effects with raloxifene suggests that it may be a safer agent than tamoxifen for use as a chemopreventative in high-risk postmenopausal women [3] therefore, raloxifene has very recently become a new option for breast cancer prevention now available for physicians and their patients. [Pg.1116]


See other pages where Breast cancer effect is mentioned: [Pg.111]    [Pg.111]    [Pg.550]    [Pg.221]    [Pg.221]    [Pg.239]    [Pg.241]    [Pg.245]    [Pg.338]    [Pg.117]    [Pg.182]    [Pg.17]    [Pg.25]    [Pg.106]    [Pg.117]    [Pg.118]    [Pg.118]    [Pg.119]    [Pg.130]    [Pg.133]    [Pg.1119]    [Pg.93]    [Pg.186]    [Pg.219]    [Pg.221]    [Pg.221]    [Pg.268]    [Pg.280]    [Pg.336]    [Pg.392]    [Pg.604]    [Pg.819]    [Pg.1011]    [Pg.1115]    [Pg.1115]    [Pg.1116]    [Pg.1128]    [Pg.1188]    [Pg.1232]   


SEARCH



© 2024 chempedia.info